JAPAN‐IDDM 2002

Methods	Country: Japan Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: No Follow‐up period: mean 1.5years Loss to follow‐up: 22
Participants	Inclusion criteria DM: Type 1 before the age of 20 years Age: 20‐50 years AER: > 30 mg/d at the time of screening in 2 consecutive sterile urine samples collected overnight Hypertensive cases: DBP < 90mm Hg with antihypertensive agents other than ACEi, CCB and AIIRA Imidapril group Number: 26 Age: 36.2 (6.7) Sex (M/F): 13/13 Captopril group Number: 26 Age: 30.9 (8.5) Sex (M/F): 6/20 Placebo group Number: 27 Age: 33.4 (7.9) Sex (M/F): 9/18 Exclusion criteria Poor glycaemic control (HbA1c > 10%) SCr > 2 mg/dL Other renal, endocrine, cardiac, liver, gastrointestinal, or connective tissue diseases
Interventions	Imidapril group 5 mg/d Captopril group 37.5 mg/d Placebo group Co‐interventions Antihypertensive agents other than ACEi, CCB and AIIRA
Outcomes	AER BP Glycaemic control
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate